{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:33:05Z","timestamp":1776681185658,"version":"3.51.2"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.msard.2020.102330","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T21:16:11Z","timestamp":1592946971000},"page":"102330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3309-2442","authenticated-orcid":false,"given":"E.C.","family":"Foo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Lily","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4156-5046","authenticated-orcid":false,"given":"H.L.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2020.102330_bib0001","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/01.wnl.0000324422.69067.e7","article-title":"Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone","volume":"71","author":"Bosca","year":"2008","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.msard.2020.102330_bib0002","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1212\/WNL.0b013e31828cf891","article-title":"Mitoxantrone-related acute leukemia in MS: an open or closed book?","volume":"80","author":"Chan","year":"2013","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2020.102330_bib0003","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/ene.13748","article-title":"Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study","volume":"25","author":"Chartier","year":"2018","journal-title":"Eur J Neurol"},{"issue":"Pt 3","key":"10.1016\/j.msard.2020.102330_bib0004","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain."},{"issue":"12","key":"10.1016\/j.msard.2020.102330_bib0005","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/jnnp.2010.229724","article-title":"Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial","volume":"82","author":"Edan","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"2","key":"10.1016\/j.msard.2020.102330_bib0006","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/jnnp.62.2.112","article-title":"Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria","volume":"62","author":"Edan","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"5","key":"10.1016\/j.msard.2020.102330_bib0007","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1191\/1352458502ms836oa","article-title":"A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis","volume":"8","author":"Ghalie","year":"2002","journal-title":"Mult Scler"},{"issue":"9350","key":"10.1016\/j.msard.2020.102330_bib0008","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet."},{"issue":"12","key":"10.1016\/j.msard.2020.102330_bib0009","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/WNL.0b013e318211c3c8","article-title":"Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes","volume":"76","author":"Hasan","year":"2011","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2020.102330_bib0010","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/WNL.0b013e3181e0f7e6","article-title":"Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS","volume":"74","author":"Kingwell","year":"2010","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2020.102330_bib0011","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/1352458511398371","article-title":"Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study","volume":"17","author":"Le Page","year":"2011","journal-title":"Mult Scler."},{"issue":"12","key":"10.1016\/j.msard.2020.102330_bib0012","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/sj.leu.2404443","article-title":"Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis","volume":"20","author":"Ledda","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.msard.2020.102330_bib0013","article-title":"Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis","author":"Li","year":"2019","journal-title":"J Neurol."},{"issue":"Pt 9","key":"10.1016\/j.msard.2020.102330_bib0014","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain"},{"issue":"18","key":"10.1016\/j.msard.2020.102330_bib0015","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.0b013e3181dc1ae0","volume":"74","author":"Marriott","year":"2010","journal-title":"Neurology."},{"issue":"21","key":"10.1016\/j.msard.2020.102330_bib0016","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1212\/WNL.0b013e318238ee00","article-title":"Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone","volume":"77","author":"Martinelli","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2020.102330_bib0017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s004150050066","article-title":"Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome","volume":"244","author":"Millefiorini","year":"1997","journal-title":"J Neurol."},{"key":"10.1016\/j.msard.2020.102330_bib0018","unstructured":"National Institute for Health and Care Excellence. British National Formulary2019[Available from:bnf.nice.org.uk."},{"issue":"10","key":"10.1016\/j.msard.2020.102330_bib0019","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/1352458511406309","article-title":"Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design","volume":"17","author":"Nicholas","year":"2011","journal-title":"Mult Scler."},{"issue":"2","key":"10.1016\/j.msard.2020.102330_bib0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cancergencyto.2008.01.004","article-title":"Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis","volume":"182","author":"Ramkumar","year":"2008","journal-title":"Cancer Genet Cytogenet."},{"issue":"6","key":"10.1016\/j.msard.2020.102330_bib0021","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/hrt.40.6.636","article-title":"Prevalence and prognosis of electrocardiographic findings in middle-aged men","volume":"40","author":"Rose","year":"1978","journal-title":"Br Heart J."},{"issue":"4","key":"10.1016\/j.msard.2020.102330_bib0022","first-page":"210","article-title":"A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis","volume":"101","author":"van de Wyngaert","year":"2001","journal-title":"Acta Neurol Belg."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:48:50Z","timestamp":1761900530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820304065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":22,"alternative-id":["S2211034820304065"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102330","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102330"}}